مورد إلكتروني
Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
| العنوان: | Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. |
|---|---|
| المصدر: | Armstrong, W B; Kennedy, A R; Wan, X S; Atiba, J; McLaren, C E; & Meyskens, F L Jr. (2000). Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 9(1), 43 - 47. UC Irvine: Retrieved from: |
| بيانات النشر: | eScholarship, University of California 2000-01-01 |
| تفاصيل مُضافة: | Armstrong, W B Kennedy, A R Wan, X S Atiba, J McLaren, C E Meyskens, F L Jr |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | The Bowman-Birk inhibitor (BBI) is a soybean-derived serine protease inhibitor and a potential cancer chemopreventive agent for humans. In this Phase I clinical trial, BBI concentrate was administered as a single oral dose to 24 subjects with oral leukoplakia. Pharmacokinetics of BBI was analyzed, and subjects were monitored clinically for toxic effects. Subjects received between 25 and 800 chymotrypsin inhibitor units (CIU) of the compound in a dose escalation trial. BBI was taken up rapidly, and a metabolic product of BBI was excreted in the urine within 24-48 h. No clinical or laboratory evidence of toxicity was observed in the study. Protease activity was also measured in buccal cells to evaluate usefulness as a biomarker. Single-dose BBI concentrate administered up to 800 CIU was well tolerated and appeared to be nontoxic. Further investigation in Phase II clinical trials is being done. |
| مصطلحات الفهرس: | Medicine and Health Sciences, Administration, Oral, Aged, Anticarcinogenic Agents: administration & dosage, adverse effects, pharmacokinetics, therapeutic use, urine, Biological Markers: analysis, Chemoprevention, Chymotrypsin: antagonists & inhibitors, Endopeptidases: analysis, Female, Follow-Up Studies, Humans, Leukoplakia, Oral: drug therapy, Male, Middle Aged, Mouth Mucosa: enzymology, Trypsin Inhibitor, Bowman-Birk Soybean: administration & dosage, Trypsin Inhibitors: administration & dosage, antineoplastic agent, Bowman Birk inhibitor, adult, aged, article, clinical article, clinical trial, controlled clinical trial, controlled study, dose response, drug blood level, drug formulation, drug metabolism, drug safety, drug tolerability, drug urine level, female, human, leukoplakia, male, priority journal, Anticarcinogenic Agents, Biological Markers, Chymotrypsin, Endopeptidases, Mouth Mucosa, Bowman-Birk Soybean, Trypsin Inhibitors, article |
| URL: | |
| الإتاحة: | Open access content. Open access content |
| ملاحظة: | 43 - 47 application/pdf Armstrong, W B; Kennedy, A R; Wan, X S; Atiba, J; McLaren, C E; & Meyskens, F L Jr. (2000). Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 9(1), 43 - 47. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/4k66t6k4 english |
| أرقام أخرى: | CDLER qt4k66t6k4 qt4k66t6k4 899745671 |
| المصدر المساهم: | UC MASS DIGITIZATION From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.ocn899745671 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |